In May 2022, substantially all assets and business activities, including those relating to the development and approval of arimoclomol, were sold to KemPharm Denmark A/S (Zevra A/S). The company currently operates as a shell biopharmaceutical entity with minimal commercial revenue and a substantially reduced operational footprint.
Cyborg Score Rationale
Orphazyme executed a near-total asset sale in May 2022, divesting its core arimoclomol program and severely constraining its operational capacity. Current revenue is minimal ($5.1M estimated for 2026), workforce is extremely reduced, and the company lacks an active commercial pipeline or near-term catalyst.
Top Insights
Asset divestiture in May 2022 transferred arimoclomol program and core operations to Zevra (formerly KemPharm Denmark), leaving Orphazyme with minimal operational assets and severely constraining future revenue generation capacity.
Revenue was $5.1 million in 2026, reflecting a severely diminished operational footprint and absence of commercialized products following the strategic restructuring and asset sale.
Workforce reduction of approximately 50% was implemented in 2022 following regulatory setback, followed by closure of commercial operations in Germany, UK, and US, indicating sustained operational contraction.
Named Competitors
Mitobridge — Develops mitochondrial therapeutics for rare neurodegenerative diseases including Niemann-Pick disease type C
Reata Pharmaceuticals — Biopharmaceutical company developing therapies for rare and orphan diseases including neurodegeneration
Akcea Therapeutics — Focuses on rare genetic diseases and lysosomal storage disorders with neurodegeneration
Cayuga Pharmaceuticals — Developing therapies for rare neurological and lysosomal storage diseases
Recent Developments
(May 2022) Asset sale to Zevra/KemPharm Denmark including arimoclomol development program and core business activities
(2022) Workforce reduced by approximately 50% and commercial operations closed in Germany, UK, and US
(2026) Estimated annual revenue of $5.1 million with minimal operational activities
Open the full interactive Orphazyme ApS report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.